Clinical Trial

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or metastatic prostate cancer. We plan to assess the PSMA PET/CT image quality following administration of two dose levels of TRDC002 to determine an acceptable dose and optimal acquisition time for obtaining diagnostic quality PET/CT images. The safety and tolerability, PK, biodistribution, dosimetry of TRDC002 will also be evaluated in this study.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-16
minor Completion pushed: 2026-06-30 -> 2026-07-31 2026-04-16
Trial Details
NCT Number NCT07236112
Lead Sponsor C Ray Therapeutics
Conditions Prostate Cancer
Enrollment 6 participants
Start Date 2026-02-08
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15